DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
OpenAI Restricts Astra AI Over Cyberattack Risks 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
STAMFORD, Conn., March 06, 2018 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:00 a.m. ET.
A live broadcast of the presentation will be available at http://ir.loxooncology.com/. An archived replay of the presentation will be available on the company’s website for 30 days following the presentation.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
1AB Media
973-271-6085
[email protected]
